| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | WH-4-023 | GDSC1000 | pan-cancer | AAC | -0.033 | 0.5 |
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | -0.097 | 0.5 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.019 | 0.5 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | 0.021 | 0.5 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | -0.049 | 0.5 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | -0.068 | 0.5 |
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | 0.034 | 0.5 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | -0.032 | 0.5 |